|
Retina Section
|
|
|
B. Kuppermann
|
|
| |
|
Diabetic Macular Edema
Chairperson: P. Kaiser
|
Back
to
Section List page |
| |
|
|
| |
A phase 2 randomized, multicenter,
dose-ranging, controlled, parallel-group trial to assess
the safety and efficacy of dexamethasone posterior segment
drug delivery system (DEX PS DDS, Postdurex) in the treatment
of persistent macular edema
B. Kuppermann
|
|
| |
|
|
| |
Macugen for DME
S. Schwartz
|
|
| |
|
|
| |
PKCbeta Inhibition for DME
L. Aiello
|
|
| |
|
|
| |
Fluocinolone implant for the
nonproliferative diabetic retinopathy, DME and progression
to PDR
R.P. Danis
|
|
| |
|
|
| |
|
Angiogenesis Inhibition Treatments
Chairpersons: B. Kuppermann, A. Adamis |
Back
to
Section List page |
| |
|
| |
Macugen for AMD
S. Schwartz
|
|
| |
|
|
| |
Ranibizumab (Lucentis) for AMD
P. Rosenfeld |
|
| |
|
|
| |
Anacortave acetate for chorodial neovascularization in
exudative age related macular degeneration (AMD)
P. Kaiser |
|
| |
|
|
| |
PEDF
for AMD
L. Wei |
|
| |
|
|
| |
A phase I/II trial of intravenous
squalamine lactate infusion for treatment of choroidal
neovascularization (CNV) associated with age-related macular
degeneration (ARMD)
H. Quiroz-Mercado
|
|
| |
|
|
| |
Retinoic
Acid for AMD
E. de Juan |
|
| |
|
Prophylaxis
of NPDR Progression to PDR
Chairperson: L.P. Aiello |
Back
to
Section List page |
| |
|
| |
Antiangiogenic
efficacy of corticosteroids
R. Danis |
|
| |
|
|
| |
PKCbeta Inhibition of NPDR
Progression and Visual Loss
L. Aiello |
|
| |
|
|
| |
Clinical management of NPDR
progression and visual loss
M. Grant |
|
| |
|
|
 |
Masked pilot study: intravitreous hylaronidase (vitrase)
effect on progression of diabetic retinopathy in humans
E. Thomas |
|
| |
|
PDT
New Drugs
Chairperson: R.P. Danis |
Back
to
Section List page |
| |
|
| |
Efficacy results of two phase
III trials of SNET2 photodynamic therapy for age-related
macular degeneration
E. Thomas |
|
| |
|
|
| |
ICG mediated photothrombosis
for the management of predominantly CNV due to AMD
M. Farah |
|
| |
|
|
| |
Retinal protection from collateral
damage from PDT
J. Burke |
|
| |
|
|
| |
Panel Discussion
P.J. Rosenfeld, P.K. Kaiser, J.M.Mones, E.L. Thomas |
|
| |
|
Targeting the Vitreous
Chairperson: M.T. Trese |
Back
to
Section List page |
| |
|
| |
Ovine hyaluronidase under investigation for vitreous hemorrage:
Integrated phase 3 randomized, pacebo-controlled trial
results
B. Kuppermann |
|
| |
|
|
| |
Plasmin
for vitreolysis
M. Trese |
|
| |
|
|
| |
Vitresolve
for vitreolysis
H. Quiroz-Mercado |
|
| |
|
|
| |
Vitreolysis / Posterior vitreous seperation indiced by
microplasmin
M. de Smet |
|
| |
|
|
| |
Ribozyme (VIT100) to proliferating cell nuclear antigen
for the treatment of proliferative vitreoretinopathy
N. Mandava |
|
| |
|
Triamcinolone
Acetonide
Chairperson: J. Jonas |
Back
to
Section List page |
| |
|
| |
Triamcinolone acetonide for
chorodial neovascularization due to DME
P. Kaiser |
|
| |
|
|
| |
Triamcinolone
for AMD
R. Danis |
|
| |
|
|
| |
High
dose intravitreal triamcinolone for treatment of intraocular
neovascular and edematous diseases
J. Jonas |
|
| |
|
|
| |
Intravitreal triamcinolone
acetonide for the treatment of macular edema associated
with central retinal vein occlusion
M. Ip |
|
| |
|
|
| |
Periocular
versus Intravitreal Triamcinolone for Uveitic CME
C. Pavesio |
|
| |
|
|
Retina
Others
Chairperson: E. De Juan Jr.
|
Back
to
Section List page |
| |
|
| |
Are
Statins or Anti-hypertensives Protective in AMD?
E. Friedman |
|
| |
|
|
| |
Retinal
protection
S. Whitcup |
|
| |
|
|
| |
Genistein
soy based TKI for retinal protection
E. de Juan |
|
| |
|
|
| |
Pharmochologic
Therapy for ROP - The Future
M. Trese |
|
| |
|
|
